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ABSTRACT
Mucopolysaccharidosis IIIA (MPS IIIA) is a lysosomal storage disease caused by
a mutation in the gene that codes for the enzyme heparan sulfamidase. The decreased
enzyme activity of heparan sulfamidase results in the accumulation of heparan sulfate (HS).
HS accumulation in the brain causes severe central nervous system (CNS) complications,
including learning and memory deficits and seizure. MPS IIIA patients have short life
expectancies and there currently is no cure for the disease. This thesis work was aimed at
identifying an early neurological phenotype in the mouse model of MPS IIIA. The data
will aid in the design of an in vivo assay for CNS correction for drug discovery. The tests
for learning and memory impairments using the Barnes maze and novel object recognition
behavioral assays did not show a neurological defect earlier than 20 weeks. These results
suggest an intact cognitive capacity for the diseased animals. To test whether seizure
threshold is altered in diseased animals, mice were administered with the chemiconvulsant
drug, pentylenetetrazol (PTZ), a GABA receptor inhibitor. The acute intravenous infusion
with PTZ did not show threshold differences between the diseased and normal mice.
However, chronic administration of a subconvulsive dose of PTZ, resulted in a difference
in seizure sensitization or kindling, as early as 4 weeks. MPS IIIA mice showed significant
resistance to kindling by 12 weeks. These seizure results not only demonstrate that we can
record a CNS specific phenotype earlier than 20 weeks, it also suggests that neuroplasticity
may be altered in diseased animals. Thus, this seizure assay may help understand the
alterations that occur in the brain circuitry of MPS IIIA affected animals.
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1.

INTRODUCTION

1.1

Project Goal
The experiments detailed in this thesis were conducted to determine if a CNS

phenotype can be detected before 20 weeks of age in the MPS IIIA mouse. An early and
robust behavioral readout for CNS-related defects has not been reported in the MPS IIIA
disease mouse model. Developing a robust functional assay of CNS progression in the
mouse model can assist in testing efficacy of novel compounds in vivo. Here, we assessed
learning and memory deficits and seizure in the MPS IIIA mice. To test memory, we used
two behavioral assays, the Barnes maze (BM) and the novel object recognition (NOR).
These tests have been reported to be sensitive in examining both acquired and natural
behavioral responses in the mice. To test seizure, we provided a challenge to the animal’s
brain circuitry responses with PTZ, a gamma-Aminobutyric acid (GABA) receptor
antagonist. Seizure induction with PTZ was used to evaluate the differences in seizure
threshold between control and diseased mice. The data collected will aid in developing
future assays to test therapies and further explore disease biology at earlier time points in
the mouse model.

1.2

Background
MPS IIIA, also known as Sanfilippo syndrome, is a recessive autosomal lysosomal

storage disease (LSD) caused by a loss-of-function mutation in the gene Nsulfoglucosamine sulfohydrolase (SGSH). SGSH is the gene that codes for the enzyme
heparan N-sulfatase, or sulfamidase. The mutation in the SGSH leads to the impaired
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synthesis of sulfamidase, an enzyme involved in the step-wise degradation of heparan
sulfate (HS) (Esposito et al., 2000; Valstar et al., 2008). The reduction of sulfamidase
activity, leads to HS accumulation in neurons primarily and other cell bodies, as a result,
impairing the CNS in MPS IIIA (Bhaumik et al., 1999; Fraldi et al., 2007).
MPS IIIA has a global incidence of 1 in every 100,000 live births (Fedele, 2015).
MPS IIIA, compared to other MPS III disorders, is the most severe form, has the earliest
onset, fastest progression of symptoms and shortest survival rate (Bhaumik et al., 1999;
Meikle et al., 1999; Valstar et al., 2010). Clinical manifestations of the disease include
severe learning disability, behavioral problems, sleep disorder and hyperactivity; with
secondary disease complications of hearing loss, diarrhea and seizures (Meyer et al., 2008;
Buhrman et al., 2014).

Children born with MPS IIIA experience normal development at

birth until they become symptomatic (Valstar et al., 2010). Clinical abnormalities show
between the ages of 2 and 6 years and neurological degeneration between 6 and 10 years
of age (Esposito et al., 2000). Severely affected children usually die by their mid to late
teenage years (Van De Kamp et al., 1981; Gliddon e Hopwood, 2004; Delgadillo et al.,
2013). Gene therapy (Lysogene, France; Abeora Therapeutics, Dallas, TX) as well as
enzyme replacement therapy (ERT) (Shire Human Genetic Therapies Inc., Cambridge,
MA) are in clinical trials but there is currently no cure for MPS IIIA.
A mouse model of MPS IIIA was established by Bhattacharyya in 2001
(Bhattacharyya et al., 2001). The mouse contains a missense mutation in the murine SGSH
gene, which replaces an aspartic acid with an asparagine (D31N) (Bhattacharyya et al.,
2001; Coutinho, Lacerda e Alves, 2012). This amino acid substitution reduces enzyme
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activity to 3-4% of that of normal enzyme levels (Roberts et al., 2007) and causes
accumulation of HS and other cellular pathology similar to what is seen in human patients.
The clinical manifestations of the disease in the mouse closely resembles the human
disease (Bhaumik et al., 1999; Hemsley e Hopwood, 2005; Fraldi et al., 2007). MPS IIIA
diseased animals at birth are indistinguishable from non-diseased littermates. At 3 weeks
of age, affected animals tend to be hyperactive (Fraldi et al., 2007). By 6-7 months of age,
significant differences in appearance and growth rates start to become apparent. Affected
animals at this age begin to look scruffy, with the fur unkempt and greasy, and develop a
hunch posture (Bhaumik et al., 1999; Crawley et al., 2006). By 10 months of age and
toward the later stages of the disease, MPS IIIA mice display aggressive behavior and
exhibit pronounced memory loss (Bhaumik et al., 1999; Hemsley e Hopwood, 2005). By
12-14 months, animals exhibit hepatosplenomegaly (enlargement of the spleen and liver)
and an expanded bladder containing 1-2 mL of turbid urine (Bhaumik et al., 1999). Death
usually occurs as a result of peripheral pathology prior to the increase in the severity of the
CNS pathology.
CNS-related defects in the MPS IIIA mice have been characterized as early as 20
weeks in behavioral assays, such as in the Morris water maze (MWM), open field test or
the negative geotaxis. The MWM assesses spatial learning and memory in mice. The test
forces the animal to swim and learn the location of a submerged platform. MPS IIIA mice
in the MWM, at 20 weeks of age, were reported to have a more difficult time in learning
the location of the platform (Fraldi et al., 2007). The open field test measures an animal’s
general movement, activity and exploratory behaviors. MPS IIIA mice at 22 weeks of age
were reported to exhibit a decrease in exploratory behaviors and in distance traveled (Lau
3

et al., 2008; Sorrentino et al., 2013). The negative geotaxis is a behavioral test that
measures the ability of the animal for reorientation when facing downwards a sloping
platform. Male MPS IIIA mice at 20 weeks of age showed a significant difference in their
ability to reorient themselves (Hemsley e Hopwood, 2005).

All these behavioral

assessments demonstrated a difference in memory, general activity and motor functions in
the MPS IIIA animals but nothing earlier than 20 weeks were reliably detected. A
behavioral assay that is a direct readout of CNS activity in younger animals, might be useful
in further characterizing the CNS disease progression in MPS IIIA mice. To the best of
our knowledge, there is no published reports on the MPS IIIA mouse model being
evaluated in a seizure assay.
Seizure is the uncoordinated electrical discharge of neurons in the brain. The
brain’s electrical signaling is maintained by the balance of the excitatory and inhibitory
neurotransmitters, glutamate and gamma-Aminobutyric acid (GABA), respectively
(Petroff, 2002). An imbalance in the activity of either of these neurotransmitters can cause
seizure episodes. Seizures are defined behaviorally as involuntary muscle jerks or spasms.
In the absence of a stimulus, MPS IIIA mice do not show visible signs of seizure. However,
we hypothesized that in response to a stimulus, MPS IIIA mice can develop seizure and
the change in seizure threshold can be scored. This seizure test can be developed into an
assay to examine CNS alterations during disease progression or as a benefit of treatment.
Although diseased animals do not exhibit seizures, seizure is a common symptom
in MPS IIIA human patients. A study on the natural history of the disease in Spain,
reported that 45% of patients develop recurring generalized seizures at a median age of 8.7
years old (Delgadillo et al., 2013; Buhrman et al., 2014). In another study, 53 of the 80
4

patients (66%) in the study experienced seizures, where the first occurrence was observed
around 11 years of age (Valstar et al., 2010). An 18 year old woman from a conducted
autopsy study, was only diagnosed with MPS IIIA after evidence of neurologic difficulty
with seizures (Rush et al., 2015).
Our attempt to understand seizure susceptibility is not solely based on clinical
seizure symptoms in patients but also on an observation made by Bruyere in the MPS IIIB
mouse model. MPS IIIB exhibits the same general disease characteristics as MPS IIIA.
MPS IIIB is caused by a deficiency in the enzyme, N-acetylglucosaminidase (NAGLU),
affecting the degradation of HS. Bruyere showed a disorganized cluster of neuronal
precursors in the rostral migratory stream (RMS) of adult MPS IIIB mice brains (Bruyere
et al., 2015). These neuronal precursors actively migrate from the subventricular zone
(SVZ) toward the olfactory bulb and other regions such as the cortex, where they
differentiate into fully mature GABAergic interneurons. These mature interneurons are
thought to play a role in regulating neuronal inhibition in the brain. This migratory defect
is yet to be confirmed in MPS IIIA. But considering the similarities between MPS IIIA
and MPS IIIB, it is possible that there may be a change in GABAergic response and it
could be measured in vivo as changes in seizure thresholds.
Seizure threshold in mice is commonly examined using a chemical agent called
pentylenetetrazol (PTZ), also known as pentetrazol, leptazol or metrazol.

PTZ was

discovered by Ladislas J. Meduna in 1934 as a circulatory and respiratory stimulant. When
PTZ is given at high doses, it causes convulsions. It has been shown that the direct binding
of PTZ to the benzodiazepine/GABA/chloride receptor complex in vitro correlates to its
convulsive effect in vivo (Squires et al., 1984). The exact mechanism of PTZ is not fully
5

Figure 1 Mechanism of PTZ
(A) The brain’s neuronal activity is maintained by the balance of GABA and Glutamate neurotransmitters.
(B) PTZ is a GABA antagonists proposed to inhibit inhibitory functions of GABA. The increase in
excitation produces seizures.

understood but evidence suggests that it stimulates the CNS by antagonizing the inhibitory
transmission of the neurotransmitter GABA (Kaminska, Lukasiuk e Kaczmarek, 1994).
PTZ inhibits the GABA-activated Cl-influx to increase depolarization in the cell, thus,
eliciting seizures (Figure 1).
PTZ has been widely used for both acute and chronic induction of seizures to
investigate efficacy of anti-epileptic drugs (AED) (Purpura Dp, 1972; Loscher, 2011; Dhir,
2012). The intravenous (IV) delivery of PTZ serves as an acute screen of seizure activity
for AEDs and has been reported to be advantageous over a subcutaneous (SC)
administration (Mandhane, Aavula e Rajamannar, 2007). The IV infusion, particularly,
offers a more consistent and reliable measurement of seizure thresholds (Nutt, Taylor e
Little, 1986). A more chronic method to determine seizure susceptibility is through
kindling. Kindling is the gradual increase in cellular discharge from a sporadic lowintensity electrical or chemical stimulant to the limbic system that climaxes to a full-blown
seizure episode (Racine, 1978).

Kindling involves chronic administration of a sub6

convulsive dose, either SC or intraperitoneal (IP), until a decrease of seizure threshold is
achieved (Da Silva, Pereira e Elisabetsky, 1998; Dhir, 2012). Both the IV infusion and
kindling have been extensively studied for models of seizure development.

We conducted this thesis study to examine two aspects of CNS function in the MPS
IIIA mouse model, learning and memory and seizure. First, we assessed the animal
model’s progressive memory deficits in the Barnes Maze (BM) and the Novel Object
Recognition (NOR) behavioral tests. The BM was developed by Carol Barnes in 1979 as
a dry-land maze, eliminating the stress of swimming in the MWM. The BM has long been
used in mice to measure cognitive impairment (Sunyer et al., 2007). The BM results will
compliment data from MWM in MPS IIIA mice.

The NOR is a task designed to

particularly evaluate recognition memory. An animal’s preference to novelty, in the
absence of a positive or negative reinforcements, was first investigated by Ennaceur and
Delacour in 1988 (Ennaceur e Delacour, 1988). This behavioral assay evaluates how the
animal’s innate exploratory behaviors could be affected by memory alterations. The NOR
data will supplement findings in the BM. Finally, we determined if by challenging the
CNS, we can characterize the seizure phenotype in diseased animals. Seizure susceptibility
was evaluated by two methods: (a) PTZ-induced IV infusion and (b) PTZ-induced IP
kindling. The BM and NOR tests did not seem to indicate an impaired cognitive ability in
diseased animals. The seizure test, on the other hand, revealed a phenotype that we were
able to score prior to 20 weeks of age in the MPS IIIA mouse.
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2.

MATERIALS AND METHODS

2.1

Animals
All animal procedures were performed in accordance to national standards of the

Institutional Animal Care and Use Committee (IACUC) (protocol #A10109) at the Buck
Institute for Research on Aging (Novato, CA). Mice carrying the sulfamidase mutation,
Sgshmps3a, in the congenic C57Bl6/J background were obtained from Jackson Laboratory
(Bar Harbor, ME). Heterozygote animals were mated to establish and maintain a colony.
MPS IIIA (B6.Cg-Sgshmps3a/B6.Cg-Sgshmps3a), heterozygous (+/B6.Cg-Sgshmps3a) and
wildtype (WT) (Sgsh+/+) mice were used for experiments. To determine genotype, animals
were ear tagged (Fine Science Tools Foster City, CA) and ear samples were collected for
analysis at Transnetyx, Inc (Memphis, TN). For initial assay development, male mice were
used for all studies and aged matched C57Bl6/J mice, as an additional WT control
comparison, were ordered from Jackson Laboratory. Animals were acclimated at least 3
days prior to start of the study. Mice were group housed in individually ventilated and
temperature controlled polysulfone cages and provided with certified rodent diet (Teklad
Global Diet #2018) and water ad libitum. Environmental controls for the animal room
were set at 20-26 °C, with relative humidity of 30 to 70%, a minimum of 10 room air
changes/hour, and a 12-hour light/12-hour dark cycle.
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2.2

Barnes Maze
The Barnes Maze test was
used to examine cognitive defects in
spatial learning and memory in MPS
IIIA mice compared to the C57Bl6/J
control group at 4, 12 and 24 weeks
(Figure 2). The maze is an elevated
circular platform with 40 equally

Figure 2 Barnes Maze Experimental Set-up
Mice laboratory experiment to measure spatial learning and
memory in the Barnes maze. Visual cues of varied sizes and
color are permanently situated around the experimental room.
This behavior assay records time latency on how fast the
animal can locate an escape box.

spaced holes running along the
perimeter.

All of the holes are

blank-bottomed except for one that

leads to an “escape box”. The escape box is provided with bedding and food pellets, which
were changed after every single animal to eliminate odor biases between animals. Several
stationary visual cues were placed in the room as the animal’s reference point for locating
the escape box, and a stimulus (noise) was used to motivate an escape response. Prior to
start of any trial, the animal was habituated to the escape box for 3 minutes. After
habituation, the mouse was placed in the middle of the maze under a box. The trial starts
upon lifting the box, the stimulus (a steady noise generated by a metronome) turned on and
the animal released to find the escape box. During the trials, the animal was given up to 3
minutes on the first trial and 1 minute on subsequent trials. An additional aversive stimulus
(clapping) was given if the animal failed to locate the escape box in 1 minute. Once the
animal was in the escape box, the noise stimulus was turned off and the animal was allowed
to stay in the escape box for another minute. Time latencies were manually recorded at
9

every trial. The maze was sprayed with 70% ethyl alcohol and wiped dry to minimize
olfactory cues after every trial. An overhead camera was positioned above the maze for
video recordings, this will allow for a variety of data (speed/velocity, time latencies,
distance traveled or heat maps) to be analyzed with an automatic video tracking software
(EthoVision XT 11).
The BM was used in two different experimental designs. The first experimental
protocol was an acute 1-day acquisition phase. The acquisition phase is where the animal
initially learns to find the escape box. During the acquisition phase, the animals received
8-10 learning trials until the mice gave a time latency of less than 1 minute, in locating the
escape box, on 3 consecutive trials. The animals were tested for memory at 24 hour and
48 hour consisting of 3 trials, post the acquisition trials. The second protocol extended the
acquisition phase over 4 days and consisted of only 2 trails per day. The animals were
tested for memory on day 5 and 15.

2.3

Novel Object Recognition
The NOR test was administered to assess
recognition memory deficits in MPS IIIA mice at 4, 12
and 24 weeks. The test was conducted in an opaque
shoebox cage arena that measured 18 cm x 28 cm x 4.5
cm high. The objects, as shown on Figure 2, are plastic

Figure 3 NOR Experimental Objects
The objects used in NOR were
odorless; similar in height and texture;
different in shape and color. Objects
were washed and cleaned after every
animal to remove possible olfactory
cues.

that varied in shape and color (width=3.4-4.0 cm;
height=4.0 cm) and were placed 13 cm apart to the
floor of the cage. The cage did not contain bedding to

minimize any distractive elements and the objects were secured with tape to prevent the
10

Figure 4 Schematic of NOR Experimental Procedure
Animals were placed in an empty cage for 10 minutes during habituation. 2 identical objects are placed in
the cage and mice were allowed to explore them. To test recognition memory, one of the objects are replaced
for a novel one. Animals explored the objects for 10 minutes at each of the phases.

mouse from displacing them. An overhead camera and fluorescent lighting were mounted
above the box cage for video recording and illumination.
The NOR test consisted of three phases (Figure 4): habituation, familiarization and
test phase. During the habituation phase, a single mouse is allowed to freely explore the
empty arena. The animal was then removed and placed back to its home cage for a time
delay of 10 minutes. In the 10 minute familiarization phase, two identical objects were
introduced and animals were released on the north-east side of the cage. Animals were
then returned to their home cages for 10 minutes. During the test phase, the animal was
reintroduced back to the arena where one of the objects was replaced with a novel one and
observed for 10 minutes. Animal exploration was manually measured as nose pokes
towards the objects and verified by an automatic video tracking (EthoVision XL 11) to
analyze the animal’s interest towards the novel object.
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2.4

PTZ-Induced Seizure Test
The PTZ induced seizures either via an IV continuous infusion or IP kindling was

done to assess seizure thresholds in MPS IIIA mice when compared to C57Bl6/J control
group at 4, 12 and 24 weeks.
2.4.1

Drug
PTZ (Sigma Aldrich, St. Louis, MO) is kept in -20°C and brought up to room

temperature prior to formulation. PTZ was weighed into a glass vial and sterile 0.9% saline
was added to achieve designated concentrations. All formulations were prepared fresh on
the day of each experiment.
2.4.2

Seizure stages with PTZ induction
PTZ has been shown to elicit distinct individual seizure stages (Da Silva, Pereira e

Elisabetsky, 1998; Dhir, 2012). Animals received a single IP administration of PTZ at a
convulsive dose of 60 mg/kg and seizure activities were observed to ascertain that PTZ can
produce seizures that we are able to score in MPS IIIA.
PTZ is a fast acting drug that was able to elicit a full blown seizure within 5 minutes
post IP injection. Seizure activity progresses through three distinct stages (Figure 5). Stage
0 decreased the animal’s activity but did not produce seizures. Stage 1 showed involuntary
muscle jerks. Stage 2 is often referred to as Straub’s tail (Dhir, 2012), where the tail erects
and is perpendicular to the body. Stage 3 is a full blown body muscle contraction,
sometimes accompanied with vocalization, lasting from 7 to 30 seconds.
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Figure 5 Seizure Stages Progression with PTZ Treatment
PTZ treatment produced a well define seizure progression, that can be separated into stages. Stage 0 - animal
activity decreases with no sign of seizure; Stage 1: Myoclonic jerks - involuntary muscle jerks; Stage 2:
Straub’s tail - rigidity with tail erection perpendicular to body; Stage 3 Clonus - full body muscle contraction
with clonic episodes.

2.4.3

PTZ-induced IV Infusion
Animals were weighed prior to study start. A tail vein cannula (extended tubing

attached with a 27G ¾ needle) for an IV administration was connected to a 5 mL syringe
preloaded with PTZ. Animals were restrained and the needle inserted to the tail and
secured by tape. A Hamilton programmable infusion pump was used to deliver 10 mg/mL
of PTZ at a constant infusion rate of 50 uL/min. Time latencies from start of infusion to
the appearance of first clonus (Stage 1) and subsequent tonic forelimb and/or hindlimb
extension lasting longer than 5 seconds (Stage 3) were recorded. Infusion was stopped at
the appearance of a Stage 3 seizure. The threshold dose in mg/kg for appearance of stage
1 and stage 3 seizures was calculated using the formula: [Infusion rate of infusion (ml/min)
* time for onset of seizure (s) * concentration of PTZ (mg/mL) * 1000] / [60 * body weight
of animal (g)]. At the end of infusion and observation of seizure episodes, surviving

13

animals were anesthetized using isoflurane (4% for induction and 1.5% for maintenance)
and euthanized by cervical dislocation.
2.4.4

PTZ-induced IP Kindling
Animals were weighed for dose volume determination prior to every treatment day

and received a single IP administration of PTZ at 40 mg/kg every other day. After PTZ
injection, the animals were placed in individual clear cages for 30 minutes to observe
seizure activity. Seizure activity (Figure 5) was rated in stages as 0-no appearance of
seizure, 1-myoclonic jerk, 2-straub’s tail and 3-generalized convulsions with tonic
extensions. Seizure stages and time of onset were recorded, with animals considered
kindled if the animal produce a stage 3 seizure over 3 consecutive treatment days. Animals
who died prior to the third stage 3 are considered kindled.
2.4.5

PTZ pharmacokinetic (PK) evaluation
For brain and plasma PTZ levels, animals were assigned to study groups as

described on Table 1. Animals received a single IP administration of PTZ and were
euthanized at specified time points. Animals were anesthetized using isoflurane and blood
sample was collected via cardiac puncture into K3 EDTA anticoagulant tubes which were
kept on ice until centrifugation at 10,000 RPM for 5 min at 4°C. Animals were decapitated
to remove the brain. The brain was separated into 2 hemispheres, right and left, and placed
into two different 2 mL Eppendorf tubes. The plasma was aliquoted into two 1.5 mL
Eppendorf tubes.

Plasma and brain samples were stored in a -80°C freezer until

submission. Samples were sent to Climax Laboratories Inc. (San Jose, CA) for PTZ brain
and plasma measurements by mass spectrometry analysis.
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Table 1 Group designation for PK profile
Group1, 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1
2

Genotype

MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J
MPS IIIA
C57Bl6/J

Age

Timepoint

(weeks)

(minutes)

4
4
12
12
24
24
4
4
12
12
24
24
4
4
12
12
24
24

5
5
5
5
5
5
15
15
15
15
15
15
30
30
30
30
30
30

n=3 animals per group; PTZ at 40 mg/kg, 4 mg/mL, 10 mL/kg.
12 week samples at 5 and 15 minutes were the only data presented.
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3.

RESULTS
MPS IIIA is marked by neurological consequences, such as cognitive impairment

and seizure.

In this thesis, we assessed and demonstrate the cognition and seizure

performance of MPS IIIA mice in 1) the Barnes Maze and Novel Objection Recognition
assays to evaluate learning and memory and 2) by PTZ seizure induction experiments to
measure seizure susceptibility.

3.1

Behavioral Tests

3.1.1

The Barnes maze does not detect early spatial memory deficits in the MPS IIIA

mice
Spatial memory and learning deficits in the MPS IIIA mice have been reported at
20 weeks using the MWM (Fraldi et al., 2007) . Here we use a similar behavioral test, the
Barnes maze. The BM has been shown to be sensitive to changes in spatial learning related
to neurodegeneration (Kennard, 2012). To determine whether we can detect a deficit in
spatial learning and memory earlier than the 20 weeks reported with MWM, we tested MPS
IIIA animals in the BM.
The data from the 1-day learning and memory method suggests that diseased
animals have similar spatial learning and memory abilities as in the normal mice. The 1day BM learning method was designed to assess acute learning and memory using 9-10
consecutive trials followed by a 24 and 48 hour memory tests. As shown on Figure 6, there
was evidence of normal learning across all the ages tested as measured by performance in
each of the training trials (A-C). The average time to find the escape box during trial 1
was similar between the controls (4 weeks: 159 secs; 12 weeks: 185 secs; 24 weeks: 204
16

secs) and the diseased animals (4 weeks: 98 secs; 12 weeks: 171 secs; 24 weeks: 180 secs).
On succeeding trials, the time latencies to locate the escape box decreased for all animals.
The animal’s ability to locate the escape box seemed to be solidified by the third trial, with
a mean time of 63.02 seconds (C57Bl6/J) and 51.05 seconds (MPS IIIA). To test if the
memory was retained, animals were tested at 24 and 48 hours. All animals demonstrated
a low time latency in finding escape at 39.4 and 37.40 seconds for controls and MPS IIIA
mice respectively. Performance between the animals was not significantly different
(p<05).
The quick succession of learning trials in the 1-day protocol may have strongly
reinforced learning and memory to be able to see any differences in behavior. To determine
whether with less trials and a prolonged learning phase with BM can better assess
differences in performance, we extended the training trials over 4 days at 2 trials per day.
To provide a greater memory challenge, the memory test was conducted at day 5 (24 hours)
and then delayed until day 15.
The 4-day learning method in Figure 7 showed similar learning performance
between diseased and normal animals. The time latencies to reach the escape box decreases
over the 4 days and seemed to be established by the third day (A-B). The memory tests on
day 5 and 15 show an average time of 85.85 seconds for the controls and 94.22 seconds for
MPS IIIA. Overall, our BM results in both the 1-day and 4-day learning protocols do not
suggest a decline in learning and memory even by 24 weeks. This data suggests that even
under a variety of reinforcement conditions, 1-day with multiple trials or gradual training
over time, MPS IIIA animals in the BM will display the same learning and memory
capacity as in the normal mice.
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Figure 6 Barnes Maze 1-day Learning and Memory Curves
Mean (± SEM) time to locate escape box in seconds (s) for MPS IIIA animals 4 (A), 12 (B) and 24 (C)
weeks. Animals received a succession of 9-10 trials to remember the specific location of an escape box.
Animals were then tested for memory at 24 hour and 48 hour. MPS IIIA animals showed learning ability
during the training trials. The memory tests showed that animals are able to remember a previously
learned behavior. *No 4 week control data available at 48 hour memory test.
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Figure 7 Barnes Maze 4-day Learning and Memory Curves
Mean (±SEM) time to locate escape box in seconds (s) for MPS IIIA mice at 12 weeks (A) and 24
weeks (B). The 4-day acquisition method extended the trials to 4 days, consisting of 2 trials per day.
The animals were then tested for memory at 24 hour and 15 days. MPS IIIA showed learning ability
during the training trials and showed retention of memory at the 24 hour and 15 day tests. *There is
no 4 week data presented due to animal availability and time constraints. *No 24 hour controls
presented for 15 day memory test.
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3.1.2

Novel object recognition showed decreased exploratory behaviors
The NOR test, unlike the BM or MWM, relies on the rodent’s spontaneous

exploratory behavior with no positive or negative reinforcements, such as a reward or
punishment. The animals were tested using the NOR assay to determine if the natural
tendency of an animal to explore a novel object can be used to detect alterations in
recognition memory.
The NOR data are presented on Figure 6. In the familiarization session (A-C), all
the animals showed similar number of exploration pokes between the two identical objects.
The diseased animals seem to exhibit lower number of nose pokes as compared to controls
but the difference was not significant. The mean numbers of nose pokes for controls were
30.51 at 4 weeks, 50.67 at 12 weeks and 33.83 at 24 weeks. The mean number of nose
pokes for MPS IIIA were 24.25 at 4 weeks, 36.75 at 12 weeks and 21.59 at 24 weeks. The
number of nose poke for MPS IIIA at 24 week MPS IIIA (C) decreases as compared to the
controls. The difference however, was not significant.
When the novel object was presented to the animals (D-F), the control animals
showed a significant increase in nose pokes towards the new object (4 wks: p<0.0001; 12
wks: p=0.0126; 24 wks: p=0.0051). In contrast, the diseased animals did not seem to show
recognition interest for the novel object (4 wks: p=0.4699; 12 wks: p=0.7360; 24 wks:
p=0.4286). MPS IIIA mice at 24 weeks consistently do not explore the objects (F) as much
as the controls.
This NOR data indicates that although the assay can detect differences between
control and MPS IIIA animals, there is a decrease in exploratory behavior in older MPS

20

IIIA mice that is similar to previous reports (Lau et al., 2008; Sorrentino et al., 2013). The
magnitude of difference between the normal and diseased animals was not within a
significant range. Furthermore, diseased animals presented a generally low interest to the
objects. This overall lack of object interest can confound results obtained with the NOR
assay.
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Figure 8 10 Minute Novel Object Exploration Scores
Exploration scores were measured as individual nose pokes that were manuallyscored for a duration of 10
minutes in MPS IIIA animals at 4, 12 and 24 weeks. (A-C) Animals showed the same number of nose
pokes when presented with two identical objects. (D-F) Control animals showed a significant increase in
the number of nose pokes towards the novel object, as compared to MPS IIIA mice. There was a decrease
in exploration behaviors in MPS IIIA during familiarization and introduction of the novel object. Bars
represent mean ± SEM; *p=0.0126, **p=0.0051 and ****p<0.0051.
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3.2

PTZ-induced Seizure Tests
The results from BM did not suggest cognitive decline even at 24 weeks. The

results with NOR also did not demonstrate a conclusive difference between normal and
MPS IIIA animals. Perhaps stimulation of the CNS might bring about a phenotype that is
CNS specific and can be measured prior to 20 weeks. To determine if seizure susceptibility
is altered in MPS IIIA mice, we administered PTZ via the IV infusion and IP kindling
experimental methods.
3.2.1

There is no significant difference in seizure thresholds with PTZ-induced seizure

via the IV infusion
The time latency for the onset of a full blown stage 3 seizure is presented in Figure
9A. Animals were administered with 10 mg/mL of PTZ at a slow constant infusion rate of
50 uL/min and the appearance of seizure stages were observed and recorded and the seizure
threshold dose were calculated. There were no significant difference (p=0.58) in the onset
of stage 3 seizures between the control and diseased animals. There was also no significant
difference in seizure threshold as presented in Figure 9B. Similar threshold doses elicited
stage 3 seizures for all animals (4 weeks: 69.7 ± 13.1 mg/kg C57; 66.3 ± 20 mg/kg MPS
IIIA, 12 weeks: 53.6 ± 3.9 mg/kg C57; 62.4 ± 22.3 mg/kg MPS IIIA and 24 weeks: 68.9 ±
5.9 mg/kg C57; 62.6 ± 15.6 mg/kg MPS IIIA).
The data on the induction of seizure via an acute IV infusion collectively indicates
that there was no detectable difference on seizure onset and threshold between normal and
diseased animals via this method.
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Figure 9 PTZ-induced Seizures via IV Infusion
PTZ was administered at 10 mg/mL at a constant rate of 50 uL/min. The onset of the first sign of seizure and
a full blown epileptic episode was recorded. Threshold doses at mg/kg was calculated based on animal body
weight, PTZ concentration, the IV infusion rate and seizure onset (seconds). (A) Seizure thresholds dose did
not show a significant difference at 4, 12 and 24 weeks. The same dose elicit similar seizures in the animals
(B) The time latency (s) for the onset of stage 3 seizure was not significant, p=0.58. This data was not
normalized to animal body weight.
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3.2.2

There was a delay in the onset of PTZ-induced IP kindling
An acute method of inducing seizure with PTZ was not able to show differences in

seizure thresholds. We then examined if by using a chronic kindling method, we can see
a defect in the adaptive changes in seizure susceptibility in MPS IIIA mice as compared to
normal mice. Animals were administered with a subconvulsive dose of PTZ at 40 mg/kg
every other day and observed for seizure onset, stages and time to kindle.
The kindling results are presented in Figure 10.

Unexpectedly, there was a

consistent delay in the kindling behavior of MPS IIIA mice starting at 4 weeks. On
average, 72% of all the animals tested kindled. For MPS IIIA mice: 60% of the 4 week
old mice kindled after 22 treatments, 67% after of the 12 week old mice kindled after 24
treatments and 60% of the 24 week old mice kindled after 18 treatments. For C57Bl6/J
mice: 83% of the 4 week old kindled after 10 treatments, 100% of the 12 week old mice
kindled after 11 treatments and 60% of the 24 week old mice kindled after 17 treatments.
For MPS IIIA heterozygous mice: 40% of the 4 week old mice kindled after 16 treatments,
88% of 12 week old mice kindled after 12 treatments, 57% of 24 week old mice kindled
after 5 treatments. For MPS IIIA WT mice: 67% of 4 week old mice kindled after 10
treatments, 67% of 12 week old mice kindled after 11 treatments and 50% of 24 week old
mice kindled after 4 treatments. The delay in kindling was found to be significant at 12
weeks, p=0.0015, and 24 weeks, p=0.0027. Our findings with the chronic IP kindling seem
to indicate that MPS IIIA mice are resistant to repeated subconvulsive PTZ stimulation.
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3.2.4

Similar PTZ levels at a single dose of 40 mg/kg
To confirm that the PK of PTZ is not altered in MPS IIIA mice and that the kindling

effect was not due to changes in PTZ brain penetration, we measured brain and plasma
PTZ levels at 5 and 15 minutes following a subconvulsive dose of 40 mg/kg.
As shown in Figure 11, PTZ brain concentrations for MPS IIIA were comparable
to normal controls (wildtype and heterozygous) at both time points. At 5 and 15 minutes,
the PK trends the same with that of reported PTZ curves at 55 and 85 mg/kg doses
(Yonekawa, Kupferberg e Woodbury, 1980). Furthermore, plasma concentrations (Figure
11B insert) indicated good peripheral distribution for PTZ. This data agrees with prior
work showing that PTZ biodistributes readily and its availability is only limited by the dose
levels (Mandhane, Aavula e Rajamannar, 2007).
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50

Figure 10 PTZ-induced Seizures via
IP Kindling
Male 4, 12 and 24 week MPS IIIA mice
received a single IP dose of PTZ at 40
mg/kg every other day until they
kindled. Kindling was achieved after 3
consecutive PTZ dose produced a stage
3 seizure.
MPS IIIA WT and
Heterozygous animals were added as
controls. (A) There was a delay in
kindling starting at 4 weeks. (B-C) A
significant difference in onset of
kindling is seen at 12 weeks,
**p=0.0015, and at 24 weeks with the
**, p=0.0027.
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Figure 11 PTZ Brain Levels
Animals received a single IP dose of PTZ at 40 mg/kg. Brain and plasma (insert) were collected at 5 and
15 minutes. Solid colored lines are PTZ levels from in-house study. Lighter broken lines are published
PTZ levels. (A) Brain PTZ levels were the same for all animals tested at 5 and 15 minutes. (B) The PK
curve of PTZ seems to follow what has been reported for PTZ PK levels at 55and 85 mg/kg (Yonekawa,
Kupferberg e Woodbury, 1980).
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4.

DISCUSSION
In this study, we investigated potential early CNS phenotypes in the MPS IIIA

mice: spatial learning and memory and seizure threshold. In general, we found that both
the Barnes maze and novel object recognition assays do not detect a robust phenotype
earlier than 20 weeks. But, with the PTZ seizure assay, CNS stimulation showed a
significant delay in kindling response by 12 weeks, with a slight trend as early as 4 weeks.
Based on published results, animal work with the MPS IIIA mouse model has not been
able to consistently demonstrate CNS-related defects earlier than 20 weeks of age. The
seizure sensitivity data in diseased animals can be exploited to advance the understanding
of disease biology. Furthermore, a seizure assay can be developed to screen for viable
therapies.
4.1

Barnes Maze fails to detect cognitive defects in MPS IIIA mice
The Barnes maze was used to test spatial learning and memory in MPS IIIA mice.

Prior work has shown that BM can measure CNS-related cognitive impairments. Our
analysis however, did not show a performance difference between normal and MPS IIIA
mice at 4, 12 and 24 weeks of age. Learning abilities appeared normal as both the control
and diseased animals consistently learned to locate the escape box with the same amount
of trials. Memory also appeared intact as the mouse was able to locate the escape box at 24
hours, 48 hours and even 15 days after having learned the task. This data suggests that
there may not be a significant cognitive impairment in MPS IIIA animals before 24 weeks
of age in the BM.
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The results of the BM conflict with reported results using MWM. In MWM, a
difference in spatial learning and memory has been reported in various publications
between normal and MPS IIIA mice (Crawley et al., 2006; Fraldi et al., 2007). A possible
confounding factor between these two assays is stress. Stress may have increased the
sensitivity to cognitive defects in MWM. Mice that were subjected to both MWM and BM
assays were tested for the stress hormone, corticosterone. Corticosterone levels were higher
in animals subjected to MWM compared to BM tests (Chu et al., 2003; Harrison, Hosseini
e Mcdonald, 2009). BM-tested animals, after corticosterone injection, showed greater
impaired memory, confirming that stress can directly impact performance (Harrison,
Hosseini e Mcdonald, 2009).
Performance can also be altered by other stress-induced behaviors that are different
between BM and MWM, such as thigmotaxis and passivity. Thigmotaxis is when an
animal swims closer to the wall, “wall-hugging”, and passivity is the reduction in
swimming speed or frequent floating. Both are behaviors exhibited by the animals when
using the MWM that occur in response to a stressful environment. These behaviors can
affect the results of a MWM experiment.

As the animal’s anxiety increases, the time

latency for escape may also increases. There may be a difference in stress response
between normal and MPS IIIA animals that can confound the analysis of the maze results.
The data can be misinterpreted as a decrease in spatial learning and memory specifically,
when in fact there was minimal or no defect at all. Thigmotaxis and passivity are not noted
in the Barnes maze.
The differences in the mazes likely affect the kind of data being generated. The
MWM do not report a phenotype earlier than 20 weeks. It’s possible that the stress factor
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present allowed some distortion of the parameters being measured. This fact about the
MWM brings into question the robustness of the maze. The BM being a potentially less
stressful version of MWM did not reveal any differences even by 24 weeks. Although the
BM has been established for memory assessment, it’s possible that it is not sensitive
enough to identify phenotypic differences in the MPS IIIA mice. To further determine if
there are learning and memory deficits in the diseased mice before 24 weeks when some
of the problems in the mazes are addressed, we employed the novel object recognition
assay.
4.2

Poor recognition and general lack of interest in objects for MPS IIIA mice
The NOR is an attractive test to use as it does not require long animal training and

offers no external motivation, positive reinforcement or punishment as compared to BM or
MWM (Antunes e Biala, 2012). Furthermore, novelty recognition requires a higher
cognitive skill from the mice since the memory is only presented once, relative to repetitive
training of the behavior in BM (Ennaceur e Delacour, 1988). The NOR is an assay for a
more natural cognitive behavior in the animal.
Our data showed recognition memory deficits by 24 weeks. This agrees with prior
work showing altered cognitive behavior at this age (Hemsley e Hopwood, 2005; Fraldi et
al., 2007; Lau et al., 2008; Sorrentino et al., 2013). But data from these other assays (water
maze, open field or negative geotaxis) was able to discern a significant decrease in
performance for the MPS IIIA animals. The range of difference in the NOR was small. In
addition, it appears that the MPS IIIA mice had an overall reduced interest in exploring
objects. Thus, it is difficult to interpret whether the loss of novel object recognition should
be attributed to the inability to remember a familiar object or to the lack of interest for
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objects in general. This decrease in exploratory behavior, even at the initial presentation
of the objects, could have reduced the resolution of the data.
While NOR and MWM or BM are able to track CNS disease progression in MPS
IIIA mice with greater sensitivity, they are not direct measurements of CNS activity. An
assay that can challenge the CNS directly in order to elicit a specific neurological reaction
can perhaps measure an early CNS phenotype in MPS IIIA mice.
4.3

A significant effect in PTZ chronic kindling in MPS IIIA mice
Although seizure is prevalent in MPS IIIA patients, it has not been reported in the

mouse model. We chose to induce seizure using a convulsive drug for the following
reasons. First, drug-induced seizures produce brain related phenotypes, as the compound
we used, in this case PTZ, targets neurotransmitter receptors in the CNS. Second, drug
levels and subsequent seizure induction can be controlled to accurately measure changes
in intensity and threshold of seizure. Lastly, Seizure induced by PTZ is a well-known assay
to quantify seizure onset and has been used to determine drug efficacy for AEDs (Orloff,
Williams e Pfeiffer, 1949; Mandhane, Aavula e Rajamannar, 2007).
We utilized two seizure assays to test different aspects of seizure threshold, the IV
infusion and IP kindling. The IV infusion has been reported to be an accurate technique to
record seizure threshold doses in mice (Mandhane, Aavula e Rajamannar, 2007). The IV
infusion conceivably can detect neurotransmitter defects that are present in the CNS.
Initially anticipating that there may not be a major difference in neurotransmitter balance
or GABA receptor activity in MPS IIIA mice but there may be a difference in how the CNS
adapts to PTZ stimulation, a repeated dose of PTZ was administered. The repeated
administration of a sub convulsive dose of PTZ elicits an imbalance in neuronal activity
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over time (Da Silva, Pereira e Elisabetsky, 1998; Dhir, 2012). This is defined as kindling.
Similar to published reports, we were able to score the stages and timing of seizure
development in both the IV infusion and IP kindling methods (Da Silva, Pereira e
Elisabetsky, 1998; Dhir, 2012).
PTZ via an IV infusion elicited the same seizure effect in both normal and MPS
IIIA animals. The fact that a similar PTZ dose elicited the same seizure excitation in the
animals (Figure 12A and 12B) may mean that there is no defect in GABA receptor or
neurotransmitter imbalance in MPS IIIA mice. The infusion data here supports the BM
results obtained, where there was no difference between the WT and MPS IIIA at any age.
Surprisingly, our data revealed a delay in seizure kindling when MPS IIIA mice
were repeatedly stimulated (Figure 12D). This result is interesting because based on
human clinical data we hypothesized that MPS IIIA mice would be more sensitive to
seizure induction and would have a reduced threshold to PTZ compared to control mice.
Instead, MPS IIIA mice appear to be more resistant to PTZ. When we measure the PTZ
levels in the brain, the concentrations were the same in MPS IIIA and normal mice. This
demonstrates that the distribution of PTZ is similar between mice and thus, validates the
seizure phenotype.
As unexpected as our initial seizure data is, it opens new avenues for opportunities
to fully understand the nuerological consequences of lysosomal function impairement to
maintaining homeostatis in the brain. In order to expand our understanding of how brain
mechanisms adjust in the presence of an insult, glutamate and GABA activity can be
measured to determine the stability of these neurotransmitters with chronic PTZ dosing.
This will begin to elucidate the molecular mechanism involved. In addition, rescue of the
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disease with gene therapy as has been reported (Fraldi et al., 2007; Aronovich e Hackett,
2015). Future experiments attempting to genetically correct the disease in the CNS of
young animals can determine whether seizure is a reliable phenotype to measure for an
assay.
PTZ induction produced the earliest CNS specific phenotype recorded. Kindling
difference was statistically significant at 12 weeks with a large range for assay
development. The subsequent normalization of the seizure threshold will validate PTZ
kindling as a method for assessing the benefit of novel drug therapies for MPS IIIA.

Figure 12 Depiction of PTZ-induced Seizure Responses in MPS IIIA mice
Shaded middle area indicates a possible mechanism of action starting with GABA receptor inhibition by PTZ
and resulting in an imbalance of brain neurotransmitters to cause seizures. (A) In a normal animal, increasing
concentration of PTZ by way of IV infusion leads to increase in seizure intensity. (B) In a MPS IIIA diseased
animal, increasing PTZ also increases seizure intensity. (C) During the kindling experiments, a sub-convulsive
dose of PTZ is delivered by IP injection. On day 1, no seizure is observed. Subsequent doses of the same
amount of PTZ eventually sensitizes the animal leading to seizure. (D) The same frequency of sub-convulsive
PTZ dosing does not appear to affect MPS IIIA mice.
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5.

CONCLUSION
This thesis project presents findings on an early CNS behavior phenotype in MPS

IIIA mice. We are the first to characterize seizures across three age groups of MPS IIIA
animals. In contrast to the data obtained with the learning and memory assays, PTZinduced seizures yielded a significant difference at 12 weeks.

The delayed onset of

kindling seizure was unexpected but nonetheless, this was an early phenotypic change that
appears to have a wider range of difference between control animals to warrant further
investigation and assay development. Our results can therefore help establish a working
in vivo assay, where seizure is a possible endpoint in the MPS IIIA disease model.
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